Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Atea Pharmaceuticals (AVIR) Enterprise Value (2019 - 2026)

Atea Pharmaceuticals' Enterprise Value history spans 8 years, with the latest figure at -$256.0 million for Q1 2026.

  • Quarterly Enterprise Value rose 39.83% to -$256.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$256.0 million through Mar 2026, up 39.83% year-over-year, with the annual reading at -$301.8 million for FY2025, 64.11% up from the prior year.
  • Enterprise Value came in at -$256.0 million for Q1 2026, up from -$301.8 million in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$256.0 million in Q1 2026 to a low of -$859.3 million in Q3 2024.
  • The 5-year median for Enterprise Value is -$608.1 million (2023), against an average of -$576.0 million.
  • Year-over-year, Enterprise Value plummeted 45.48% in 2024 and then surged 64.11% in 2025.
  • Atea Pharmaceuticals' Enterprise Value stood at -$646.7 million in 2022, then increased by 10.61% to -$578.1 million in 2023, then tumbled by 45.48% to -$841.0 million in 2024, then surged by 64.11% to -$301.8 million in 2025, then increased by 15.18% to -$256.0 million in 2026.
  • Per Business Quant, the three most recent readings for AVIR's Enterprise Value are -$256.0 million (Q1 2026), -$301.8 million (Q4 2025), and -$329.3 million (Q3 2025).